Floatz logo

Vorinostat

Niemann-Pick Disease, Type C1

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Small moleculePhase 1/2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Niemann-Pick Disease, Type C1 cohort.

Asset / SponsorPhaseRating
Hydroxypropyl-Beta-Cyclodextrin
Cyclo Therapeutics, Inc.
Phase 3BB
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1/2CCC
Lithium, Elemental
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1C

Same molecule, other indications

Vorinostat is also rated in:

acute myeloid leukemia with 11q23 abnormalitiesDormant
BB
Indicative · Phase 2
68 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative · Phase 2
68 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →